Shanghai Ark Biopharmaceutical Co., Ltd. ("ArkBio") today announced the initiation of a Phase II clinical study of AK0610, a ...

Toragen, Inc., an oncology biopharmaceutical company focused on the development of TGN-S15, their oral, small molecule drug candidate, today announced the receipt of a grant from the Gates Foundation.

The findings confirm that allosteric inhibition of integrase is clinically viable, validating a new antiviral drug class.

Researchers uncover that ALV-J boosts miR-155 to suppress TRAF3 and STAT1, weakening immune responses and promoting viral ...

A humble kitchen spice could pack a powerful antiviral punch. Researchers have found that compounds in cardamom seeds can ...

An international research team has successfully identified the initial high-resolution structures of the herpes simplex virus ...

Early broadly neutralising antibody responses against the E1E2 glycoprotein seem to be important for preventing persistence ...

Evolutionary changes in RNA binding and antiviral activity result in diverse IFIT1 functions across mammals, even among closely related species.

NanoViricides, Inc., a publicly traded company (NYSE Amer:NNVC) (the "Company"), announced that its clinical lead drug NV-387 ...

Cidara’s lead candidate, CD388, is a long-acting antiviral prophylactic designed for universal prevention of seasonal and ...

NanoViricides, Inc., a publicly traded company (NYSE American:NNVC) (the "Company"), announced that its clinical lead drug NV ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, announces that the ...